Dynavax Technologies | DVAX - Vermögenswerte



Vermögenswerte Veränderung Datum
AbbVie USD 133.96B 62M 2025-12
Adma Biologics USD 624.24M 55.56M 2025-12
Agenus USD 226.8M 7.09M 2025-12
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Gilead Sciences USD 59.02B 490M 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Merck USD 129.55B 12.02B 2025-09
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
TG Therapeutics USD 1.06B 38.23M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12